CN105055797A - Traditional Chinese medicine composite for treating cerebral thrombosis and application thereof - Google Patents
Traditional Chinese medicine composite for treating cerebral thrombosis and application thereof Download PDFInfo
- Publication number
- CN105055797A CN105055797A CN201510525200.3A CN201510525200A CN105055797A CN 105055797 A CN105055797 A CN 105055797A CN 201510525200 A CN201510525200 A CN 201510525200A CN 105055797 A CN105055797 A CN 105055797A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- rhizoma
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Abstract
The invention belongs to the technical field of traditional Chinese medicine and relates to a traditional Chinese medicine composite for treating the cerebral thrombosis and the application thereof. The traditional Chinese medicine composite is prepared with ligusticum wallichii, peach kernels, frankincense, myrrh, veratrum nigrum, rhizoma alismatis, dandelion, fructus forsythiae, calendula officinalis flowers, horseradish tree leaves, evening primrose, platycodon grandiflorum, prepared rehmannia roots and licorice roots. The traditional Chinese medicine composite has the effect of invigorating the blood circulation, removing stasis, promoting the circulation of qi, relieving pains, reinforcing qi and nourishing blood, meanwhile, the traditional Chinese medicine composite also has the effect of relieving the turbidity, decreasing the lipid and lowering the blood glucose level and blood pressure, the composite is used for preventing and treating the cerebral thrombosis, and the effect is remarkable.
Description
Technical field
The invention belongs to technical field of Chinese medicines, be specifically related to a kind of Chinese medicine composition for the treatment of cerebral thrombosis and uses thereof.
Background technology
Acute cerebrovascular disease is the disease of the hurried cerebral vessels circulatory disturbance of one group of onset, and be neural commonly encountered diseases and frequently-occurring disease, disability rate and fatality rate are all higher.Cerebral thrombosis is one of three large common acute cerebrovascular, Basic disease cause causes Aldosterone, luminal stenosis obturation due to self pathological changes such as atherosclerosiss or on narrow basis, forms thrombosis, cause brain regional blood flow to reduce or blood supply interruption, brain tissue ischemia anoxia causes the focal neurological symptom of softening downright bad appearance.The common site of cerebral thrombosis is internal carotid artery, middle cerebral artery, vertebral artery and basilar artery, thus causes the position of these tremulous pulse blood supplies to form infringement due to hypoxic-ischemic.Clinical main manifestations is occur that suddenly inclined side upper and lower extremities numbness is unable, facial hemiparalysis, slurred speech etc., along with advancing of disease, time serious, the complication such as pulmonary infection, cerebrocardiac syndrome, injury of hypothalamus, syndrome of inapropriate ADH and multiple organ failure, MOF can be produced.
Western medical treatment cerebral thrombosis, to improve the blood circulation of Cerebral Region, promotion neurological functional recovery as early as possible for principle, conventional Therapeutic Method has Hemodilution Therapy, thrombolytic therapy and anticoagulant therapy.Thrombolytic therapy is applicable to the extreme early of cerebral thrombosis, needs to treat in 3-6 hour in morbidity, treats in time, Be very effective within this time period, but exceedes this time period and apply thrombolytic therapy again, and effect is very low.Hemodilution Therapy and anticoagulant therapy are carried out mainly through intravenous drip relative medicine, and Therapeutic Method is inconvenient.Western medicine therapy side effect is obvious, expensive, and the treatment later stage also needs prolonged administration of drugs maintaining treatment effect, prevention of recurrence.
Cerebral thrombosis belongs to TCM Stroke category, is referred to as ancient times such as apoplexy, coma, hemiplegia, hemiplegia, apoplexy etc.According to the dialectical principle treated, cerebral thrombosis can be divided into again the cards such as the resistance of wind sun network, obstruction of collateral caused by windphlegm, phlegm-heat accumulation, blood stasis due to qi deficiency, deficiency of kidney essence.Cow-bezoar bolus for resurrection and restorative bolus are the more common medicines of current Chinese traditional treatment apoplexy, have certain curative effect, but price are very expensive for treatment cerebral thrombosis.
Chinese patent application 201410113186.1 discloses a kind of Chinese medicine composition for the treatment of cerebral thrombosis and preparation method thereof, and it obtains primarily of following raw material: Semen Persicae 10-50 part, Rhizoma Et Radix Notopterygii 10-20 part, Flos Sophorae 5-20 part, Radix Cynanchi Paniculati 5-15 part, Radix Rehmanniae Preparata 5-10 part, Bulbus Lilii 5-15 part, Flos Lonicerae 5-15 part, Radix Salviae Miltiorrhizae 1-10 part, Fructus Lycii 5-15 part, Poria 9-15 part, Rhizoma Chuanxiong 9-15 part, Radix Angelicae Dahuricae 5-15 part, berberine 0.2-9 part, Radix Paeoniae Alba 5.5-15 part, Radix Rhodiolae 6-9 part, Radix Glycyrrhizae 10-15 part.This Chinese medicine composition has the function of blood circulation promoting and blood stasis dispelling, anti-inflammatory and antalgic, but it is at reduction blood glucose, blood fat and blood pressure, and the function of the aspects such as prevention cerebral thrombosis is not remarkable.
Chinese traditional treatment cerebral thrombosis, has low drug side effect, the features such as treating both the principal and secondary aspects of a disease, has a extensive future, and seeks a kind of rapid-action, good effect, efficacy stability, and cost medicine that is low and that be easy to the treatment cerebral thrombosis promoted the use of is this area urgent problem.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of Chinese medicine composition for the treatment of cerebral thrombosis, this Chinese medicine composition has blood circulation promoting and blood stasis dispelling, promoting the circulation of QI to relieve pain, benefiting QI and nourishing blood and reduce blood pressure, effect of blood fat and blood pressure, possess therapeutic effect significantly, efficacy stability, treating both the principal and secondary aspects of a disease, applied widely and be easy to advantages such as applying.In addition, the present invention also provides corresponding manufacturing process to be made and facilitate easy-to-use finished product preparation under the prerequisite ensureing curative effect by this Chinese medicine.
Chinese medicine composition of the present invention is prepared from by the raw material of following parts by weight:
Rhizoma Chuanxiong 26-35 part, Semen Persicae 23-30 part, Olibanum 18-25 part, Myrrha 16-22 part, Rhizoma et radix veratri (Radix Rhizoma Veratri) 15-22 part, Rhizoma Alismatis 17-23 part, Herba Taraxaci 18-27 part, Fructus Forsythiae 11-18 part, Calendula officinalis flower 13-18 part, leaf of Moringa 10-16 part, Radix Oenotherae erythrosepalae 10-19 part, Radix Platycodonis 12-19 part, Radix Rehmanniae Preparata 9-15 part and Radix Glycyrrhizae 6-13 part.
Preferably, described Chinese medicine composition is prepared from by the raw material of following parts by weight:
Rhizoma Chuanxiong 26 parts, 23 parts, Semen Persicae, Olibanum 18 parts, Myrrha 16 parts, Rhizoma et radix veratri (Radix Rhizoma Veratri) 15 parts, Rhizoma Alismatis 17 parts, Herba Taraxaci 18 parts, Fructus Forsythiae 11 parts, Calendula officinalis spend 13 parts, leaf of Moringa 10 parts, Radix Oenotherae erythrosepalae 10 parts, Radix Platycodonis 12 parts, Radix Rehmanniae Preparata 9 parts and 6 parts, Radix Glycyrrhizae.
Preferably, described Chinese medicine composition is prepared from by the raw material of following parts by weight:
Rhizoma Chuanxiong 35 parts, 30 parts, Semen Persicae, Olibanum 25 parts, Myrrha 22 parts, Rhizoma et radix veratri (Radix Rhizoma Veratri) 22 parts, Rhizoma Alismatis 23 parts, Herba Taraxaci 27 parts, Fructus Forsythiae 18 parts, Calendula officinalis spend 18 parts, leaf of Moringa 16 parts, Radix Oenotherae erythrosepalae 19 parts, Radix Platycodonis 19 parts, Radix Rehmanniae Preparata 15 parts and 13 parts, Radix Glycyrrhizae.
Preferably, described Chinese medicine composition is prepared from by the raw material of following parts by weight:
Rhizoma Chuanxiong 33 parts, 27 parts, Semen Persicae, Olibanum 21 parts, Myrrha 18 parts, Rhizoma et radix veratri (Radix Rhizoma Veratri) 17 parts, Rhizoma Alismatis 20 parts, Herba Taraxaci 24 parts, Fructus Forsythiae 15 parts, Calendula officinalis spend 16 parts, leaf of Moringa 12 parts, Radix Oenotherae erythrosepalae 16 parts, Radix Platycodonis 18 parts, Radix Rehmanniae Preparata 13 parts and 9 parts, Radix Glycyrrhizae.
Present invention also offers the preparation method of described Chinese medicine composition, mainly comprise the following steps:
(1) get Rhizoma Chuanxiong, Semen Persicae, Fructus Forsythiae, Calendula officinalis flower, leaf of Moringa and Radix Platycodonis, cross 200-270 mesh sieve after pulverizing, doubly add according to the 12-15 of fine powder gross weight the alcoholic solution that concentration expressed in percentage by volume is 60%-80%, reflux, extract, 2-3 time, each return time is 2-3h, filters, and retains filtering residue, merge extractive liquid, reclaim ethanol, being evaporated to relative density under 60-65 DEG C of environment is the extractum of 1.20-1.25, spraying dry, cross 80-100 mesh sieve, obtain extractum fine powder;
(2) get Olibanum, Myrrha, Rhizoma et radix veratri (Radix Rhizoma Veratri), Rhizoma Alismatis, Herba Taraxaci, Radix Oenotherae erythrosepalae, Radix Rehmanniae Preparata and Radix Glycyrrhizae, pulverize, mix with step (1) filtering residue, add the soak by water 3-4h of medical material gross weight 6-8 times amount, filter; Filtering residue adds the soak by water 2.5-2h of medical material gross weight 4-6 times amount, filters; Merge twice filtrate, being evaporated to relative density under 60-65 DEG C of environment is the extractum of 1.20-1.25, drying under reduced pressure, crosses 80-100 mesh sieve, obtain extractum fine powder after pulverizing; Fully mix with the extractum fine powder of step (1), obtain this Chinese medicine composition.
Utilize modern general Chinese medicine preparation technology, Chinese medicine composition of the present invention can be made into the finished product preparation of clinical needs, as dosage forms such as granule, pill, powder, tablet or capsules.
The prescription analysis of medicament composing prescription of the present invention:
Medicament composing prescription of the present invention with Rhizoma Chuanxiong and Semen Persicae for monarch drug, blood-activating and qi-promoting, wind-expelling pain-stopping; With Olibanum, Myrrha, Rhizoma et radix veratri (Radix Rhizoma Veratri), Rhizoma Alismatis and Herba Taraxaci for ministerial drug, blood-activating and qi-promoting, eliminating stasis to stop pain, clearing away heat-damp and promoting diuresis; With Fructus Forsythiae, Calendula officinalis flower, leaf of Moringa, Radix Oenotherae erythrosepalae, Radix Platycodonis and Radix Rehmanniae Preparata for adjuvant drug, dispersing swelling and dissipating binds, heat-clearing and toxic substances removing, the liver and the kidney tonifying, nourishing blood and invigorating qi; With Radix Glycyrrhizae for making medicine, invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, coordinating the actions of various ingredients in a prescription, makes all medicines arrange in pairs or groups, synergism, jointly reach effect of promoting blood circulation to remove obstruction in the collateral, eliminating stasis to stop pain, benefiting QI and nourishing blood, blood fat reducing, blood sugar lowering and blood pressure lowering, to cerebral thrombosis, there is treatment and preventive effect very significantly.
The present invention also discloses a kind of purposes of above-mentioned Chinese medicine composition, i.e. the purposes of above-mentioned Chinese medicine composition in preparation treatment cerebral thrombosis medicine.Chinese medicine composition clinical testing data of the present invention shows, Chinese medicine composition of the present invention reaches 65% for the treatment cure rate of cerebral thrombosis, and total effective rate reaches 91.25%, and all far above matched group, therapeutic effect is remarkable; Show that traditional Chinese medicine composition for treating cerebral thrombosis of the present invention obviously can lower blood lipid to the measurement result of blood lipids index before and after patient treatment, have the function of significant regulating lipid metabolism, blood fat reducing ability is obviously better than matched group simultaneously.And animal test results display, Chinese medicine composition of the present invention significantly can improve the hemorheology index of blood stasis model rat, remarkable to the therapeutic effect of blood stasis; The affect result of the test of Chinese medicine composition of the present invention on cerebral thrombosis rat model plasma lysophosphatidic acid and phosphatidic acid level shows simultaneously, compare with model control group, after Chinese medicine composition of the present invention is intervened in advance, the rising trend of rat LPA and PA level is significantly suppressed, thus prove that Chinese medicine composition of the present invention has the effect suppressing LPA and PA level to raise, for thrombosis and cerebral ischemia, there is significant preventive effect.
Compared with prior art, Chinese medicine composition of the present invention has following technical advantage:
(1) compared with positive control drug Xueshuan xinmaining Tablet, Chinese medicine composition Chinese medicine composition of the present invention not only in blood circulation promoting and blood stasis dispelling effect more remarkable, suppressing the rising of LPA and PA, antithrombotic and cerebral ischemia aspect are also significantly better than positive control medicine, this shows that present composition medicament composing prescription is reasonable, in treatment and prevention cerebral thrombosis, have significant synergism.
(2) Chinese medicine composition of the present invention has rapid-action in treatment cerebral thrombosis, good effects etc. treat advantage significantly, simultaneously, Chinese medicine composition of the present invention can obviously reduce blood glucose, blood fat and blood pressure level, also there is certain inhibitory action to arteriosclerosis and thrombosis, there is the effect of significant prevention cerebral thrombosis.
(3) Chinese medicine composition of the present invention has promoting blood circulation to remove obstruction in the collateral, eliminating stasis to stop pain and benefiting QI and nourishing blood effect, also has efficacy stability simultaneously, rapid-action, toxic and side effects is low and be easy to advantages such as applying.
Detailed description of the invention
Below will further describe the present invention by specific embodiment, the present invention is not limited only to following examples.Within the scope of the invention or not departing from content of the present invention, spirit and scope, the change carried out the present invention, combination or replacement, be apparent for a person skilled in the art, be included within the scope of the present invention.
embodiment 1
The embodiment of the present invention 1 Chinese medicine composition is prepared from by the raw material of following parts by weight:
Rhizoma Chuanxiong 26 parts, 23 parts, Semen Persicae, Olibanum 18 parts, Myrrha 16 parts, Rhizoma et radix veratri (Radix Rhizoma Veratri) 15 parts, Rhizoma Alismatis 17 parts, Herba Taraxaci 18 parts, Fructus Forsythiae 11 parts, Calendula officinalis spend 13 parts, leaf of Moringa 10 parts, Radix Oenotherae erythrosepalae 10 parts, Radix Platycodonis 12 parts, Radix Rehmanniae Preparata 9 parts and 6 parts, Radix Glycyrrhizae.
Preparation method is as follows:
(1) get Rhizoma Chuanxiong, Semen Persicae, Fructus Forsythiae, Calendula officinalis flower, leaf of Moringa and Radix Platycodonis, cross 270 mesh sieves after pulverizing, add according to 12 times of fine powder gross weight the alcoholic solution that concentration expressed in percentage by volume is 75%, reflux, extract, 2 times, each return time is 2h, filters, and retains filtering residue, merge extractive liquid, reclaim ethanol, being evaporated to relative density under 60 DEG C of environment is the extractum of 1.20, spraying dry, cross 100 mesh sieves, obtain extractum fine powder;
(2) get Olibanum, Myrrha, Rhizoma et radix veratri (Radix Rhizoma Veratri), Rhizoma Alismatis, Herba Taraxaci, Radix Oenotherae erythrosepalae, Radix Rehmanniae Preparata and Radix Glycyrrhizae, pulverize, mix with step (1) filtering residue, add the soak by water 3h of medical material gross weight 6 times amount, filter; Filtering residue adds the soak by water 2h of medical material gross weight 4 times amount, filters; Merge twice filtrate, being evaporated to relative density under 60 DEG C of environment is the extractum of 1.20, drying under reduced pressure, crosses 100 mesh sieves, obtain extractum fine powder after pulverizing; Fully mix with the extractum fine powder of step (1), obtain this Chinese medicine composition.
embodiment 2
The embodiment of the present invention 2 Chinese medicine composition is prepared from by the raw material of following parts by weight:
Rhizoma Chuanxiong 35 parts, 30 parts, Semen Persicae, Olibanum 25 parts, Myrrha 22 parts, Rhizoma et radix veratri (Radix Rhizoma Veratri) 22 parts, Rhizoma Alismatis 23 parts, Herba Taraxaci 27 parts, Fructus Forsythiae 18 parts, Calendula officinalis spend 18 parts, leaf of Moringa 16 parts, Radix Oenotherae erythrosepalae 19 parts, Radix Platycodonis 19 parts, Radix Rehmanniae Preparata 15 parts and 13 parts, Radix Glycyrrhizae.
Preparation method is with embodiment 1.
embodiment 3
The embodiment of the present invention 3 Chinese medicine composition is prepared from by the raw material of following parts by weight:
Rhizoma Chuanxiong 33 parts, 27 parts, Semen Persicae, Olibanum 21 parts, Myrrha 18 parts, Rhizoma et radix veratri (Radix Rhizoma Veratri) 17 parts, Rhizoma Alismatis 20 parts, Herba Taraxaci 24 parts, Fructus Forsythiae 15 parts, Calendula officinalis spend 16 parts, leaf of Moringa 12 parts, Radix Oenotherae erythrosepalae 16 parts, Radix Platycodonis 18 parts, Radix Rehmanniae Preparata 13 parts and 9 parts, Radix Glycyrrhizae.
Preparation method is with embodiment 1.
embodiment 4
The embodiment of the present invention 4 Chinese medicine composition is prepared from by the raw material of following parts by weight:
Rhizoma Chuanxiong 28 parts, 25 parts, Semen Persicae, Olibanum 21 parts, Myrrha 19 parts, Rhizoma et radix veratri (Radix Rhizoma Veratri) 20 parts, Rhizoma Alismatis 18 parts, Herba Taraxaci 25 parts, Fructus Forsythiae 15 parts, Calendula officinalis spend 17 parts, leaf of Moringa 15 parts, Radix Oenotherae erythrosepalae 14 parts, Radix Platycodonis 15 parts, Radix Rehmanniae Preparata 13 parts and 11 parts, Radix Glycyrrhizae.
Preparation method is with embodiment 1.
chinese medicine composition pharmacodynamic study of the present invention:
test one: Chinese medicine composition of the present invention is on the impact of blood stasis model hemorheology of rat
1, experimental animal: regular grade SD rat 90, body weight 260-320g, male and female half and half, are divided into 9 groups at random, often organize 10.
2, trial drug and dosage regimen:
A group: by Chinese medicine composition obtained for the embodiment of the present invention 1, be deployed into water the suspension that concentration is 0.6g/ml, 0.4g/ml and 0.2g/ml, for subsequent use.Get 3 groups of rats, be labeled as A group high dose group (dosage 3.0g/kg), middle dosage group (dosage 2.0g/kg) and low dose group (dosage 1.0g/kg), high dose group concentration is the drug suspension of 0.6g/ml, middle dosage group concentration is the drug suspension of 0.4g/ml, low dose group concentration is the drug suspension of 0.2g/ml, according to dosage every day gavage 1 time, successive administration 7 days.
B group: trial drug is the Chinese medicine composition that the embodiment of the present invention 2 obtains, and dosage regimen is with A group.
Positive controls: positive control drug is Xueshuan xinmaining Tablet (the accurate word Z20030145 of traditional Chinese medicines, Jilin Huakang Pharmaceutical Co., Ltd), be deployed into the suspension of 0.6g/ml with water, get 1 group of rat, by dosage gastric infusion every day 1 time of 3.0g/kg, successive administration 7 days.
Model control group: get 1 group of rat, isometric(al) normal saline gavage every day 1 time, continuous gavage 7 days.
Normal group: get 1 group of rat, the same model control group of dosage regimen.
3, the foundation of rat blood stasis models:
After last administration 1h, except blank group, all the other respectively organize rat skin lower injection adrenalin hydrochloride 10 μ g/kg totally 2 times, interval 4h.Between double injection adrenalin hydrochloride, front and back are respectively every 2h, and rat being immersed water temperature is 5min in the frozen water of 4 DEG C, causes blood stasis model.After modeling, water is can't help in the equal fasting of each group rat, and the next morning anaesthetizes with pentobarbital sodium, heart extracting blood 4ml, shake up standing in the anticoagulant tube that wherein 2ml injects rapidly containing heparin, after measuring whole blood viscosity, by its low-speed centrifugal, isolate blood plasma, measure plasma viscosity and hematocrit (Hct); 2ml injects in the silication pipe containing 3.8% sodium citrate in addition, for detecting erythrocyte sedimentation rate (ESR), finally calculates ESR equation K value.
4, result of the test: as shown in table 1.
Table 1 Chinese medicine composition of the present invention is on the impact of blood stasis model hemorheology of rat
Continued 1 Chinese medicine composition of the present invention is on the impact of blood stasis model hemorheology of rat
Note: compare with Normal group, model control group
# p< 0.05,
## p< 0.01; Compare with model control group, drug test group
* p< 0.05,
* p< 0.01.
5, conclusion (of pressure testing):
Test data shows, and compare with Normal group, the equal significance of hemorheology index of rat blood stasis models group increases, consistent with the hemorheology feature of blood stasis type disease, can be used for research Chinese medicine composition of the present invention to the therapeutic effect of cerebral thrombosis.
Compare with model control group, Chinese medicine composition A group of the present invention, namely the Chinese medicine composition high dose group that the embodiment of the present invention 1 is obtained and middle dosage group all significantly can improve the hemorheology index of blood stasis model rat, action effect is better than positive controls, and low dose group also can reduce the level of each hemorheology index to a certain extent.
Compare with model control group, Chinese medicine composition B group of the present invention, namely the Chinese medicine composition high dose group that the embodiment of the present invention 2 is obtained significantly can reduce the hemorheology index level of rat, effect is better than positive controls, and middle dosage group and low dose group also have certain reduction effect to hemorheology index level.
To sum up, Chinese medicine composition of the present invention is remarkable to the therapeutic effect of blood stasis, can be used for the clinical treatment of cerebral thrombosis.
test two: Chinese medicine composition of the present invention is on the impact of cerebral thrombosis rat model plasma lysophosphatidic acid and phosphatidic acid level
1, test principle and object: lysophosphatidic acid (LPA) and phosphatidic acid (PA) are all the intermediate products of phospholipid metabolism.Under normal circumstances, the content of LPA in blood plasma is very low, and the platelet of human or animal by the effect release LPA of phospholipase, makes LPA level in blood plasma raise after being subject to stimulated by thrombin activation.LPA can assemble and smooth muscle contraction by stimulating platelet, promotes blood vessel endothelium hypertrophy, plays an important role in blood coagulation and thrombosis.PA is a kind of early stage releaser of cerebral ischemia, produces in the 24h of ischemia, its level increase the degree reflecting cerebral hypoxia ischemia, relevant with the excessive formation of oxygen-derived free radicals.This test proves its preventive effect to cerebral thrombosis by research Chinese medicine composition of the present invention to the impact of LPA and PA level in cerebral thrombosis rat model blood plasma.
2, the foundation of cerebral thrombosis in rats model:
By rat with after 1% pentobarbital sodium (30-40mg/kg) intraperitoneal injection of anesthesia, dorsal position is fixed on operating-table.Skin is longitudinally cut in the positive middle part of neck, and otch is about 2cm, and be separated musculi colli, right carotid of dissociating, is upwards separated external carotid artery and internal carotid artery from common carotid artery crotch.Ligation external carotid artery, be then separated internal carotid artery to basis cranii direction, at basis cranii, place isolates arteria pterygopalatina, and its root of ligation, only retain internal carotid artery and enter basis cranii trunk.Ligation common carotid artery, temporary 2 micro-arterial clamps folder that keeps at a certain distance away closes internal carotid artery, below proximal part vascular clamp, common carotid artery place eye scissors cuts an osculum, taken out in insertion the conduit of Thrombus inducer thrombin 10U and normal saline 0.01ml fixing after, remove proximal part vascular clamp, a small amount of blood inflow catheter head end, place about 10min and form a microthrombus, then another vascular clamp is removed, slowly this thrombosis and thrombin are injected internal carotid artery, extract conduit, and by the ligation of common carotid artery incision, sew up the incision, postoperative single cage is raised.
Sham operated rats operative process is the same, injects normal saline but not Thromboembolus and thrombin.
3, test grouping and dosage regimen:
Regular grade SD rat 60, body weight 280-350g, male and female half and half, are divided into 6 groups at random, often organize 10.
Model control group: get 1 group of rat, isometric(al) normal saline gavage every day 1 time, continuous gavage 7 days.
Drug test group: by Chinese medicine composition obtained for the embodiment of the present invention 3, be deployed into water the suspension that concentration is 0.6g/ml, 0.4g/ml and 0.2g/ml, for subsequent use.Get 3 groups of rats, be labeled as drug test group high dose group (dosage 3.0g/kg), middle dosage group (dosage 2.0g/kg) and low dose group (dosage 1.0g/kg), high dose group concentration is the drug suspension of 0.6g/ml, middle dosage group concentration is the drug suspension of 0.4g/ml, low dose group concentration is the drug suspension of 0.2g/ml, according to dosage every day gavage 1 time, successive administration 7 days.
Positive controls: positive control drug is Xueshuan xinmaining Tablet (the accurate word Z20030145 of traditional Chinese medicines, Jilin Huakang Pharmaceutical Co., Ltd), is deployed into the suspension of 60%, gets 1 group of rat with water, by dosage gastric infusion every day 1 time of 3.0g/kg, successive administration 7 days.
Sham operated rats: get 1 group of rat, isometric(al) normal saline gavage every day 1 time, continuous gavage 7 days.
Normal group: get 1 group of rat, isometric(al) normal saline gavage every day 1 time, continuous gavage 7 days.
4, test method:
Model control group: prohibit diet 12h after last gavage, with reference to the method for building up Modling model of above-mentioned cerebral thrombosis in rats model.Postoperative 3h, with 1% pentobarbital sodium (30-40mg/kg) intraperitoneal injection of anesthesia, through abdominal aortic blood 4ml, detects the level of LPA and PA in blood plasma.
Drug test group: the same model control group of test method.
Positive controls: the same model control group of test method.
Sham operated rats: prohibit diet 12h after last gavage, carries out sham-operation.Postoperative 3h, with 1% pentobarbital sodium (30-40mg/kg) intraperitoneal injection of anesthesia, through abdominal aortic blood 4ml, detects the level of LPA and PA in blood plasma.
Normal group: prohibit diet 12h after last gavage, with 1% pentobarbital sodium (30-40mg/kg) intraperitoneal injection of anesthesia, through abdominal aortic blood 4ml, detects the level of LPA and PA in blood plasma.
5, result of the test: as shown in table 2.
Table 2 respectively group rat plasma LPA, PA level compares
Note: compare with model control group, positive controls and drug test group
* p< 0.05,
* p< 0.01; Compare with Normal group, sham operated rats and model control group
▲ p< 0.05,
▲ ▲ p< 0.01.
6, conclusion (of pressure testing):
Test data show, compared with Normal group, LPA and the PA level of rats in sham-operated group without significant change, and LPA and the PA water mean pole of model control group rat significantly reduce (
p< 0.01).
Compare with model control group, after Chinese medicine composition of the present invention that is high, middle dosage is intervened in advance, the rising trend of rat LPA and PA level is significantly suppressed, and effect is better than positive controls.And the effect that low dose group also has certain suppression LPA, PA level to raise, effect is suitable with positive controls.
To sum up, Chinese medicine composition of the present invention has the effect suppressing LPA and PA level to raise, and has significant preventive effect for thrombosis and cerebral ischemia.
test three: the clinical trial of Chinese medicine composition of the present invention
(1) case and diagnostic criteria
1, diagnostic criteria
With reference to the diagnostic criteria of Chinese Medical Association about cerebral thrombosis and cerebral embolism:
1) often fall ill under rest state;
2) most of nothing is obviously had a headache and is vomitted;
3) morbidity can be comparatively slow, how to be in progress gradually, or to carry out in stage, how relevant with cerebral atherosclerosis, also shows in arteritis, hematopathy etc.;
4) Clear consciousness or slight obstacle in general morbidity rear 1-2 day;
5) Internal Carotid System and (or) Vertebro-basilar System sings and symptoms is had;
6) Lumbar puncture CSF generally should not contain blood;
7) CT examination finds cerebral location of lesions.
Meet above diagnostic criteria patient and informed consent, be ready that experimenter all can inclusive criteria.
2, get rid of and reject case standard
1) transient ischemic attack;
2) check and confirm to merge the atrial fibrillation person that causes cerebral embolism by the cerebral tumor, cerebral trauma, cerebral parasitosis, dysbolismus, rheumatic heart disease, coronary heart disease, other heart disease;
3) gestation or women breast-feeding their children, to this medicine composition allergy sufferers;
4) the severe primary diseases such as liver, kidney, hemopoietic system and hormonal system are associated with, psychotic;
5) do not meet inclusive criteria, not by regulation medication, cannot judge that curative effect or data do not affect the treatment or safety judgement person entirely.
(2) clinical trial protocol
1, physical data
Go out by diagnosis standard screening the clinical volunteers patient that 160 examples meet diagnosis of cerebral thrombosis standard, be divided into treatment group and matched group two groups at random, often organize each 80 examples, age 42-69 year, 56.5 years old mean age.The influence factors such as two groups of ages, state of an illness distributions, through statistical procedures, there was no significant difference, meets a point set condition.
2, trial drug and test method
Treatment group: Chinese medicine composition fill capsule of the present invention prepared by the embodiment of the present invention 3, every capsules drug containing 0.55g, each serving with 2, every day 3 times.
Matched group: take Xueshuan xinmaining Tablet (the accurate word Z20030145 of traditional Chinese medicines, Jilin Huakang Pharmaceutical Co., Ltd), each serving with 2, every day 3 times.
Two groups was all 1 course for the treatment of with 4 weeks, evaluated curative effect after 3 courses for the treatment of, and the lipid-lowering effect of trade-off medicine by treatment Patients Before And After blood lipids index.
3, curative effect determinate standard
Judge according to " Chinese medical disease Standardization of diagnosis and curative effect " that State Administration of Traditional Chinese Medicine formulates:
Cure: symptom and sign disappear, and substantially can live on one's own life;
Take a turn for the better: symptom and sign take a turn for the better, the action of energy cane, or basic living can be taken care of oneself;
Do not heal: symptom and sign unchanged.
4, therapeutic effect
1) two groups of patient clinical comparitive study, as shown in table 3.
Table 3 therapeutic effect
Clinical data shows, and Chinese medicine composition of the present invention reaches 65% for the treatment cure rate of cerebral thrombosis, and total effective rate reaches 91.25%, all far above matched group, proves traditional Chinese medicine composition for treating Be very effective of the present invention.
2) two groups of patients with lipid's Indexes Comparison, as shown in table 4.
Blood lipids index before and after table 4 patient treatment
Note: compare with before treatment, * after treatment
p< 0.05; *
p< 0.01.
Clinical testing data shows, and traditional Chinese medicine composition for treating cerebral thrombosis of the present invention obviously can lower blood lipid, has the function of significant regulating lipid metabolism, and blood fat reducing ability is obviously better than matched group.
5, conclusion (of pressure testing)
This clinical trial adopts the prescription drugs Xueshuan xinmaining Tablet for the treatment of cerebral thrombosis conventional on the market at present as a control group, by comparing with the therapeutic effect of Chinese medicine composition of the present invention, highlights the curative effect of Chinese medicine composition of the present invention.Clinical testing data shows, and Chinese medicine composition of the present invention is remarkable for the therapeutic effect of cerebral thrombosis, and has obvious lipid-reducing function, and can be used as cerebral thrombosis treatment drug use, clinical generalization value is high.
Claims (7)
1. treat the Chinese medicine composition of cerebral thrombosis for one kind, it is characterized in that, described Chinese medicine composition is prepared from by the raw material of following parts by weight: Rhizoma Chuanxiong 26-35 part, Semen Persicae 23-30 part, Olibanum 18-25 part, Myrrha 16-22 part, Rhizoma et radix veratri (Radix Rhizoma Veratri) 15-22 part, Rhizoma Alismatis 17-23 part, Herba Taraxaci 18-27 part, Fructus Forsythiae 11-18 part, Calendula officinalis flower 13-18 part, leaf of Moringa 10-16 part, Radix Oenotherae erythrosepalae 10-19 part, Radix Platycodonis 12-19 part, Radix Rehmanniae Preparata 9-15 part and Radix Glycyrrhizae 6-13 part.
2. the Chinese medicine composition for the treatment of cerebral thrombosis as claimed in claim 1, it is characterized in that, described Chinese medicine composition is prepared from by the raw material of following parts by weight: Rhizoma Chuanxiong 26 parts, 23 parts, Semen Persicae, Olibanum 18 parts, Myrrha 16 parts, Rhizoma et radix veratri (Radix Rhizoma Veratri) 15 parts, Rhizoma Alismatis 17 parts, Herba Taraxaci 18 parts, Fructus Forsythiae 11 parts, Calendula officinalis spend 13 parts, leaf of Moringa 10 parts, Radix Oenotherae erythrosepalae 10 parts, Radix Platycodonis 12 parts, Radix Rehmanniae Preparata 9 parts and 6 parts, Radix Glycyrrhizae.
3. the Chinese medicine composition for the treatment of cerebral thrombosis as claimed in claim 1, it is characterized in that, described Chinese medicine composition is prepared from by the raw material of following parts by weight: Rhizoma Chuanxiong 35 parts, 30 parts, Semen Persicae, Olibanum 25 parts, Myrrha 22 parts, Rhizoma et radix veratri (Radix Rhizoma Veratri) 22 parts, Rhizoma Alismatis 23 parts, Herba Taraxaci 27 parts, Fructus Forsythiae 18 parts, Calendula officinalis spend 18 parts, leaf of Moringa 16 parts, Radix Oenotherae erythrosepalae 19 parts, Radix Platycodonis 19 parts, Radix Rehmanniae Preparata 15 parts and 13 parts, Radix Glycyrrhizae.
4. the Chinese medicine composition for the treatment of cerebral thrombosis as claimed in claim 1, it is characterized in that, described Chinese medicine composition is prepared from by the raw material of following parts by weight: Rhizoma Chuanxiong 33 parts, 27 parts, Semen Persicae, Olibanum 21 parts, Myrrha 18 parts, Rhizoma et radix veratri (Radix Rhizoma Veratri) 17 parts, Rhizoma Alismatis 20 parts, Herba Taraxaci 24 parts, Fructus Forsythiae 15 parts, Calendula officinalis spend 16 parts, leaf of Moringa 12 parts, Radix Oenotherae erythrosepalae 16 parts, Radix Platycodonis 18 parts, Radix Rehmanniae Preparata 13 parts and 9 parts, Radix Glycyrrhizae.
5. the Chinese medicine composition of the treatment cerebral thrombosis as described in as arbitrary in claim 1-4, is characterized in that: described Chinese medicine composition is made into granule, pill, powder, tablet or capsule.
6. prepare as arbitrary in claim 1-4 as described in the method for Chinese medicine composition for the treatment of cerebral thrombosis, it is characterized in that comprising the following steps:
(1) get Rhizoma Chuanxiong, Semen Persicae, Fructus Forsythiae, Calendula officinalis flower, leaf of Moringa and Radix Platycodonis, cross 200-270 mesh sieve after pulverizing, doubly add according to the 12-15 of fine powder gross weight the alcoholic solution that concentration expressed in percentage by volume is 60%-80%, reflux, extract, 2-3 time, each return time is 2-3h, filters, and retains filtering residue, merge extractive liquid, reclaim ethanol, being evaporated to relative density under 60-65 DEG C of environment is the extractum of 1.20-1.25, spraying dry, cross 80-100 mesh sieve, obtain extractum fine powder;
(2) get Olibanum, Myrrha, Rhizoma et radix veratri (Radix Rhizoma Veratri), Rhizoma Alismatis, Herba Taraxaci, Radix Oenotherae erythrosepalae, Radix Rehmanniae Preparata and Radix Glycyrrhizae, pulverize, mix with step (1) filtering residue, add the soak by water 3-4h of medical material gross weight 6-8 times amount, filter; Filtering residue adds the soak by water 2.5-2h of medical material gross weight 4-6 times amount, filters; Merge twice filtrate, being evaporated to relative density under 60-65 DEG C of environment is the extractum of 1.20-1.25, drying under reduced pressure, crosses 80-100 mesh sieve, obtain extractum fine powder after pulverizing; Fully mix with the extractum fine powder of step (1), obtain this Chinese medicine composition.
7. the purposes of the arbitrary described Chinese medicine composition of claim 1-4 in preparation treatment cerebral thrombosis medicine.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510525200.3A CN105055797A (en) | 2015-08-25 | 2015-08-25 | Traditional Chinese medicine composite for treating cerebral thrombosis and application thereof |
| CN201610332021.2A CN105902771A (en) | 2015-08-25 | 2015-08-25 | Application of traditional Chinese medicine composition in preparation of medicines for treating cerebral thrombosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510525200.3A CN105055797A (en) | 2015-08-25 | 2015-08-25 | Traditional Chinese medicine composite for treating cerebral thrombosis and application thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610332021.2A Division CN105902771A (en) | 2015-08-25 | 2015-08-25 | Application of traditional Chinese medicine composition in preparation of medicines for treating cerebral thrombosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105055797A true CN105055797A (en) | 2015-11-18 |
Family
ID=54485474
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610332021.2A Withdrawn CN105902771A (en) | 2015-08-25 | 2015-08-25 | Application of traditional Chinese medicine composition in preparation of medicines for treating cerebral thrombosis |
| CN201510525200.3A Withdrawn CN105055797A (en) | 2015-08-25 | 2015-08-25 | Traditional Chinese medicine composite for treating cerebral thrombosis and application thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610332021.2A Withdrawn CN105902771A (en) | 2015-08-25 | 2015-08-25 | Application of traditional Chinese medicine composition in preparation of medicines for treating cerebral thrombosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN105902771A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1985965A (en) * | 2006-07-23 | 2007-06-27 | 李锡尧 | Medicine for treating coronary heart disease and cerebral thrombus and its preparing method |
| CN101066303A (en) * | 2006-05-05 | 2007-11-07 | 文振生 | Medicine for treating cerebral thrombus, cerebral angiosclerosis, apoplexy and hemiplegia and its prepn |
-
2015
- 2015-08-25 CN CN201610332021.2A patent/CN105902771A/en not_active Withdrawn
- 2015-08-25 CN CN201510525200.3A patent/CN105055797A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101066303A (en) * | 2006-05-05 | 2007-11-07 | 文振生 | Medicine for treating cerebral thrombus, cerebral angiosclerosis, apoplexy and hemiplegia and its prepn |
| CN1985965A (en) * | 2006-07-23 | 2007-06-27 | 李锡尧 | Medicine for treating coronary heart disease and cerebral thrombus and its preparing method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105902771A (en) | 2016-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103989970B (en) | A kind of Chinese medicine composition treating hypertension | |
| CN101306138B (en) | Chinese traditional injection preparation for treating chest stuffiness and pains and its preparation method | |
| CN104984268A (en) | Traditional Chinese medicine composition treating cerebral thrombosis and preparing method of traditional Chinese medicine composition | |
| CN102078509B (en) | Traditional Chinese medicine preparation for treating ophthalmorrhagia and preparation method thereof | |
| CN104857366A (en) | Preoperative intervention medicine composition for neurosurgery and application thereof | |
| CN101450189B (en) | Medicine for curing angiocardiopathy and cerebrovascular disease and its preparing method | |
| CN103027944A (en) | Pharmaceutical composition for preventing and treating cardiovascular and cerebrovascular disease | |
| CN105833055A (en) | Traditional Chinese medicine composition for treating hypertension, hyperlipidemia and hyperglycemia and preparing method and application thereof | |
| CN105055797A (en) | Traditional Chinese medicine composite for treating cerebral thrombosis and application thereof | |
| CN105816819A (en) | Method for preparing traditional Chinese medicine composition for treating cerebral thrombosis | |
| CN105343675A (en) | Traditional Chinese medicine preparation for treating adiposis and preparation method thereof | |
| CN1318066C (en) | Medicine for treating dysmenorrhes and preparation thereof | |
| CN104225363A (en) | Pharmaceutical preparation for treating cerebral thrombosis | |
| CN105343449A (en) | Application of medicine combination in preparing medicine for treating cerebral thrombosis | |
| CN105796823A (en) | Application of pharmaceutical composition in preparing medicine for treating cerebral thrombosis | |
| CN105194300A (en) | Pharmaceutical composition for treating cerebral thrombosis | |
| CN105232893A (en) | Application of pharmaceutical composition to preparation of medicament for treating cerebral thrombus | |
| CN103316226B (en) | Traditional Chinese medicine composition for treating coronary heart disease | |
| CN110215474B (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis and application thereof | |
| CN104940554A (en) | Chinese herbal composition for treating heart diseases | |
| CN101152247A (en) | Pharmaceutical composition for cardiovascular and cerebrovascular diseases and method for preparing the same | |
| CN106729101B (en) | Traditional Chinese medicine composition for treating post-circulation ischemic stroke and preparation method thereof | |
| CN104940279A (en) | Application of Chinese herbal composition to preparation of medicine for treating myocardial infarction | |
| CN105106786A (en) | Traditional Chinese medicine composition capable of dredging collaterals and relaxing muscles as well as preparation and production method of composition | |
| CN104208571A (en) | Traditional Chinese medicinal composition for treating cardiovascular stenosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20151118 |
|
| WW01 | Invention patent application withdrawn after publication |